Pharma Reviews: From Cipla to Glenmark, pharma companies' double-digit growth in doubt

Compliance and R&D costs in the India business are low and credit cycles are shorter and thus a rebound in the domestic market is important.
Read more: From Cipla to Glenmark, pharma companies' double-digit growth in doubt